P. freudenreichii

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the studies reviewed here, Propionibacterium freudenreichii has been most studied in (i) dairy/food microbiology (Swiss-type cheese ripening, flavor formation, and metabolic capabilities), (ii) probiotic and host–microbe interaction research (immunomodulation, gut barrier/mucus biology, and anti-cancer cell responses), and (iii) ruminant nutrition as a component of multispecies direct-fed microbial (DFM) supplements evaluated in dairy cows and beef steers (effects on rumen fermentation, pH dynamics, digestibility, immune parameters, and metabolomic profiles). Mechanistically oriented work emphasizes its distinctive propionate-producing metabolism (Wood–Werkman cycle), capacity to synthesize vitamins including B12, and stress-hardiness traits (e.g., polyphosphate, glycogen, trehalose), while newer lines of inquiry highlight bacterial extracellular vesicles as potential mediators of probiotic signaling (not yet clearly resolved in the excerpts).

The strongest evidence in these studies supports well-established roles in dairy fermentation/cheese ripening and a plausible probiotic potential mediated by microbial metabolites. In vivo evidence is most direct in the DSS-induced colitis rat model, where live P. freudenreichii and culture supernatant reduced disease activity and inflammatory markers while increasing MUC2 expression and fecal propionate, consistent with improved mucus barrier function. In ruminant studies, supplementation with DFMs that include P. freudenreichii shows measurable effects on rumen environment and fiber utilization in some contexts (e.g., improved ruminal pH pattern and increased ADF digestibility in beef steers for one formulation), and ongoing work applies high-coverage metabolomics to characterize systemic and ruminal metabolic shifts in early-lactation dairy cows; however, because these are multispecies mixtures, attribution of effects specifically to P. freudenreichii remains limited.

Key gaps include strain-specificity and causal mechanisms in vivo. Multiple studies and the review emphasize that functional properties are highly strain-dependent, yet many animal studies use multispecies DFMs, making it difficult to isolate the contribution of P. freudenreichii versus other included taxa and dose ratios. More research is needed in controlled, single-strain (or well-factorial) designs that link colonization/viability, metabolite production (e.g., propionate, acetate, vitamin B12), and host outcomes, alongside mechanistic work on candidate effectors such as secreted factors and extracellular vesicles. Finally, while cell-culture and fermented-milk studies suggest anti-cancer potential via short-chain fatty acids and apoptosis pathways, stronger translational evidence (well-powered animal tumor models and human clinical trials with defined strains and endpoints) is required to establish efficacy and safety in humans and to determine which formulations and delivery matrices are most effective.

1. What conditions has P. freudenreichii been studied for?

  • Inflammatory bowel disease–like colitis (preclinical): Studied in a dextran sodium sulfate (DSS)-induced colitis rat model and in goblet-cell culture (LS 174T) to assess mucus/MUC2 and inflammation outcomes.

  • Gastrointestinal cancers (preclinical, in vitro): Studied in human gastric cancer cells (HGT-1) using milk fermented exclusively by P. freudenreichii; also studied in human colon cancer cells (HT29) including combination with TRAIL (an apoptosis-inducing ligand).

  • Longevity/healthy aging biology (preclinical): Studied in Caenorhabditis elegans for lifespan extension and stress/pathogen resistance mechanisms.

  • Livestock digestive function and performance (animal production): Studied as part of direct-fed microbial (DFM) mixtures in early-lactation dairy cows (performance, digestibility, rumen fermentation, immune parameters; plus ruminal/plasma metabolomics) and in beef steers (ruminal pH pattern, fiber digestibility, ruminal degradation kinetics).

  • Food/probiotic functionality (general): A review describes strain-dependent probiotic features, including production of propionic acid and potential immunomodulatory effects, and notes vitamin synthesis pathways (including B12) in the genome of a reference strain.

  • Pathogen interaction (preclinical cell model, as part of a multispecies DFM): A multispecies DFM including P. freudenreichii was tested for reducing Salmonella invasion/antagonism in cell-based models (the study describes the aim and model).

2. Does it work in treating those conditions? Summarize the evidence.

  • Acute colitis (DSS rat model): Evidence supports benefit in this model.

    • Both live P. freudenreichii and culture supernatant reduced disease activity index (DAI) in DSS-induced colitis rats.

    • They decreased mRNA levels of “typical pro-inflammatory cytokines,” improved histology, and increased mucus-related outcomes (MUC2 gene/protein; immunohistochemistry showed increased intestinal MUC2).

    • They increased fecal propionate in colitis rats, consistent with a short-chain fatty acid (SCFA)-linked mechanism.

    • Limitation: This is an animal model of acute colitis; it does not establish efficacy in human IBD.

  • Gastric cancer (HGT-1 cells): Evidence supports pro-apoptotic activity in vitro, not clinical treatment.

    • Supernatant from milk fermented exclusively by P. freudenreichii induced multiple apoptosis hallmarks (e.g., DNA laddering, caspase activation, cytochrome c release, mitochondrial potential disruption).

    • It also enhanced cytotoxicity of camptothecin (a chemotherapy drug) in this cell model.

    • Limitation: Cell-line findings do not demonstrate tumor response or safety in humans.

  • Colorectal cancer mechanisms / TRAIL sensitization (HT29 cells): Evidence supports synergy in vitro.

    • P. freudenreichii supernatant or its SCFA metabolites (propionate/acetate) combined with TRAIL increased pro-apoptotic gene expression (e.g., TRAIL-R2/DR5) and decreased anti-apoptotic genes (e.g., FLIP, XIAP) in HT29 cells.

    • The combination was lethal to cancer cells but not to normal human intestinal epithelial cells (HIEC) in the reported experiments, and depended on death receptors and caspase activation; inhibition by Bcl-2 expression suggests mitochondrial pathway involvement.

    • Limitation: This supports a mechanistic rationale for adjunctive strategies, but not clinical efficacy.

  • Longevity/aging (C. elegans): Evidence supports lifespan extension in worms, not humans.

    • P. freudenreichii significantly extended lifespan vs. standard E. coli OP50 food and improved age-related biomarkers in worms.

    • Mechanistic genetics in worms implicated pathways including p38 MAPK and TGF-β signaling; activation of skn-1 was linked to increased resistance to Salmonella typhimurium challenge.

    • Limitation: Worm longevity does not directly translate to human lifespan effects.

  • Livestock outcomes (DFM mixtures including P. freudenreichii): Evidence suggests some digestive/rumen benefits in certain formulations, but effects cannot be attributed to P. freudenreichii alone.

    • In beef steers, a multispecies DFM including P. freudenreichii improved some measures (e.g., increased ADF digestibility; improved ruminal pH pattern with less time under pH 5.6) in the formulation with a higher proportion of B. licheniformis.

    • In dairy cows, studies evaluated performance, digestibility, rumen fermentation, immune parameters, and metabolomics with DFMs that included P. freudenreichii (details in the studies reviewed here are truncated, limiting conclusions).

    • Limitation: Multispecies mixtures and dose ratios confound attribution to P. freudenreichii.

3. What health benefits does it have?

  • Supports intestinal mucus barrier (preclinical): In vitro and in DSS colitis rats, P. freudenreichii (live cells or culture supernatant) increased MUC2 expression and improved colitis severity and histology, consistent with mucus-layer restoration.

  • Anti-inflammatory signaling (preclinical): In DSS colitis rats, treatment decreased mRNA levels of pro-inflammatory cytokines and improved inflammatory histology.

  • SCFA production (mechanistic): Multiple studies link benefits to propionate/acetate (SCFAs). In colitis rats, fecal propionate increased with treatment; cancer-cell studies attribute apoptosis induction partly to propionate/acetate acting on mitochondria.

  • Potential anti-cancer adjunct mechanisms (in vitro): Fermented milk/supernatants induced apoptosis in gastric and colon cancer cell lines and enhanced cytotoxic effects of camptothecin (gastric model) and TRAIL (colon model), while sparing normal intestinal epithelial cells in the reported colon model.

  • Potential pathogen resistance/immune resilience (preclinical): In C. elegans, feeding P. freudenreichii increased resistance to Salmonella typhimurium via skn-1 activation; a separate abstract describes testing a multispecies DFM including P. freudenreichii for reducing Salmonella invasion in a cell model.

  • Vitamin and metabolic capabilities (strain-dependent, review/genomics): A review notes genome-reconstructed pathways including synthesis of many vitamins “including vitamin B12” in a reference strain, and highlights hardiness traits (polyphosphate, glycogen, trehalose). Actual vitamin production in humans depends on strain, viability, and gut ecology and is not established by these studies.

  • Livestock digestive benefits (mixtures): In beef steers, a DFM mixture including P. freudenreichii improved fiber digestibility and ruminal pH pattern in one formulation; this may be relevant to rumen health under high-energy diets, but is not direct evidence of human benefit.

4. Does it have any downsides or side effects?

  • Human side effects are not established in the studies reviewed here: None of the included studies report adverse events in humans, and several are in vitro or animal studies.

  • Potential for strain-dependent variability: The review emphasizes that many properties (adaptation, probiotic effects, immunomodulation) are “highly strain-dependent,” implying that benefits (and potentially tolerability) may not generalize across products/strains.

  • Context-specific effects in ruminants: In beef steers, the DFM mixture associated with improved ruminal pH also showed higher ruminal NH3-N concentration; whether that is beneficial or undesirable depends on diet formulation and nitrogen utilization goals. This does not translate directly to human safety.

  • Immunomodulation is a double-edged concept: While immunomodulatory effects are described as “promising” in the review, the studies reviewed here do not define risks in immunocompromised hosts, nor do they provide clinical safety data.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • No human pharmacogenomic evidence in the studies reviewed here: None of the studies evaluate human genetic variants that predict response or adverse effects to P. freudenreichii.

  • Mechanistic genetics exist only in a worm model: In C. elegans, lifespan extension depended on specific genes/pathways (e.g., p38 MAPK pathway genes such as pmk-1/sek-1/mek-1; TGF-β-related pathways; and daf-2/daf-12), and resistance involved skn-1. These findings suggest plausible conserved pathways (stress response/inflammation signaling), but they are not directly actionable for human pharmacogenomics.

  • Cancer-cell pathway dependence is not pharmacogenomics: The TRAIL synergy work showed dependence on death receptors/caspases and inhibition by Bcl-2 expression in cancer cells. This indicates that tumor molecular features could influence response in vitro, but it is not evidence of patient germline genetic variation affecting outcomes.

References

  1. Effects of direct-fed microbial supplement on ruminal and plasma metabolome of early-lactation dairy cows: Untargeted metabolomics approach.
    A O Oyebade, G A Taiwo, Modoluwamu Idowu, T Sidney, O Queiroz, A T Adesogan, D Vyas, I M Ogunade (2024) - Journal of dairy science
  2. Effects of direct-fed microbial supplementation on performance and immune parameters of lactating dairy cows.
    A O Oyebade, S Lee, H Sultana, K Arriola, E Duvalsaint, C Nino De Guzman, I Fernandez Marenchino, L Marroquin Pacheco, F Amaro, L Ghedin Ghizzi, L Mu, H Guan, K V Almeida, B Rajo Andrade, J Zhao, P Tian, C Cheng, Y Jiang, J Driver, O Queiroz, L F Ferraretto, I M Ogunade, A T Adesogan, D Vyas (2023) - Journal of dairy science
  3. Co-culturing Propionibacterium freudenreichii and Bifidobacterium animalis subsp. lactis improves short-chain fatty acids and vitamin B
    Ricco Tindjau, Jian-Yong Chua, Shao-Quan Liu (2024) - Food microbiology
  4. New insights into physiology and metabolism of Propionibacterium freudenreichii.
    Anne Thierry, Stéphanie-Marie Deutsch, Hélène Falentin, Marion Dalmasso, Fabien J Cousin, Gwenaël Jan (2011) - International journal of food microbiology
  5. Effects of bacterial direct-fed microbial mixtures offered to beef cattle consuming finishing diets on intake, nutrient digestibility, feeding behavior, and ruminal kinetics/fermentation profile.
    Kaliu G Scaranto Silva, Jhones O Sarturi, Bradley J Johnson, Dale R Woerner, Alejandra M Lopez, Barbara M Rodrigues, Kaue T Nardi, Camron J Rush (2024) - Journal of animal science
  6. Dairy Propionibacterium freudenreichii ameliorates acute colitis by stimulating MUC2 expression in intestinal goblet cell in a DSS-induced colitis rat model.
    Seongho Ma, Jiah Yeom, Young-Hee Lim (2020) - Scientific reports
  7. Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells.
    Fabien J Cousin, Sandrine Jouan-Lanhouet, Marie-Thérèse Dimanche-Boitrel, Laurent Corcos, Gwénaël Jan (2012) - PloS one
  8. Propionibacterium freudenreichii CIRM-BIA 129 mitigates colitis through S layer protein B-dependent epithelial strengthening.
    Marine Mantel, Tony Durand, Anne Bessard, Ségolène Pernet, Julie Beaudeau, Juliana Guimaraes-Laguna, Marie-Bernadette Maillard, Eric Guédon, Michel Neunlist, Yves Le Loir, Gwénaël Jan, Malvyne Rolli-Derkinderen (2024) - American journal of physiology. Gastrointestinal and liver physiology
  9. Dairy Propionibacterium extends the mean lifespan of Caenorhabditis elegans via activation of the innate immune system.
    Gayeung Kwon, Jiyun Lee, Young-Hee Lim (2016) - Scientific reports
  10. The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer.
    Fabien J Cousin, Sandrine Jouan-Lanhouet, Nathalie Théret, Catherine Brenner, Elodie Jouan, Gwénaëlle Le Moigne-Muller, Marie-Thérèse Dimanche-Boitrel, Gwénaël Jan (2016) - Oncotarget
  11. A multispecies bacterial-based direct-fed microbial alleviates Salmonella invasion and supports in vitro epithelial integrity.
    Raphaele Gresse, Bruno I Cappellozza, Lena C Capern, Tine T M Knudsen, Giuseppe Copani (2024) - Journal of animal science
  12. In situ production of active vitamin B12 in cereal matrices using Propionibacterium freudenreichii.
    Bhawani Chamlagain, Tessa A Sugito, Paulina Deptula, Minnamari Edelmann, Susanna Kariluoto, Pekka Varmanen, Vieno Piironen (2018) - Food science & nutrition
  13. Combining selected immunomodulatory Propionibacterium freudenreichii and Lactobacillus delbrueckii strains: Reverse engineering development of an anti-inflammatory cheese.
    Coline Plé, Jérôme Breton, Romain Richoux, Marine Nurdin, Stéphanie-Marie Deutsch, Hélène Falentin, Christophe Hervé, Victoria Chuat, Riwanon Lemée, Emmanuelle Maguin, Gwénaël Jan, Maarten Van de Guchte, Benoit Foligné (2016) - Molecular nutrition & food research
  14. Beneficial Propionibacteria within a Probiotic Emmental Cheese: Impact on Dextran Sodium Sulphate-Induced Colitis in Mice.
    Houem Rabah, Fillipe Luiz Rosa do Carmo, Rodrigo Dias de Oliveira Carvalho, Barbara Fernandes Cordeiro, Sara Heloisa da Silva, Emiliano Rosa Oliveira, Luisa Lemos, Denise Carmona Cara, Ana Maria Caetano Faria, Gilles Garric, Marielle Harel-Oger, Yves Le Loir, Vasco Azevedo, Guillaume Bouguen, Gwénaël Jan (2020) - Microorganisms
  15. Colorectal Cancer Cells Increase the Production of Short Chain Fatty Acids byPropionibacterium freudenreichiiImpacting on Cancer Cells Survival
    Marta R Casanova, João Azevedo-Silva, Ligia R Rodrigues, Ana Preto (2018)
  16. ProbioticPropionibacterium freudenreichiirequires SlpB protein to mitigate mucositis induced by chemotherapy
    Fillipe Luiz Rosa do Carmo, Houem Rabah, Barbara Fernandes Cordeiro, Sara Heloisa da Silva, Rafaela Miranda Pessoa (2019)
  17. Propionibacterium freudenreichiiSurface Protein SlpB Is Involved in Adhesion to Intestinal HT-29 Cells
    Fillipe L R do Carmo, Houem Rabah, Song Huang, Floriane Gaucher, Martine Deplanche (2017)


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!